S2-E44 - The impact Of the COVID-19 Delta Variant on NAFLD and NASH
Send us Fan Mail Donna Cryer joins the Surfers to discuss the different effects that the Delta Variant of COVID-19 is having on different stakeholders within the Fatty Liver community. What impact is ...
2 Sep 20211h 2min
S2-E43.4 -Rethinking Cirrhosis: A Call To Action
Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation constitutes a call to action for the Surfers and our listeners. In terms of cirrhosis ...
29 Aug 202111min
S2-E43.3 - Driving A Reconsideration Of Cirrhosis In Drug Development
Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on how to drive a broader change in perspective. Once we accept the idea that c...
29 Aug 202112min
S2-E43.2 - Rethinking Cirrhosis As A Target For Drug Development
Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on why F4 might be a better target than F2/3. This conversation focuses on spec...
28 Aug 202111min
S2-E43.1 - Cirrhosis - Challenges in Treating Patients
Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis. This conversation focuses on the unique challenges in treating NASH cirrhosis. This conversation focuses ...
28 Aug 202111min
S2-E43 - Can Cirrhosis Drive Drug Development In NASH?
Send us Fan Mail Jörn Schattenberg joins the Surfers to discuss drug development in cirrhosis, which evolves into a discussion about how to drive NITs forward. Historically, NASH drug development stra...
26 Aug 202153min
S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates
Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy....
22 Aug 202112min
S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH
Send us Fan Mail Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy....
21 Aug 202112min
